Morgan Stanley lowered the firm's price target on Docebo to $26 from $28 and keeps an Equal Weight rating on the shares. On the positive side, the firm learned this was one of Docebo's strongest gross bookings quarters since 2021, however it still views Docebo as a "show-me story," the analyst tells investors following earnings.
